Latest News and Press Releases

CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered,...

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered,...

—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust——Experimental therapies with potential to prevent and treat complications of COVID-19——EDP1815 selected as...

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020––Selected enteric capsule formulation of EDP1815 for Phase 2...

—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial——Data...

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...